Wednesday - March 25, 2026
FDA Office of Prescription Drug Promotion Issues Warning Letter to ImmunityBio
March 25, 2026
WASHINGTON, March 25 -- The U.S. Department of Health and Human Services Food and Drug Administration issued the following warning letter to ImmunityBio Inc. from its Office of Prescription Drug Promotion:

* * *

Recipient: Richard Adcock, President and Chief Executive Officer, ImmunityBio, Inc., 9920 Jefferson Blvd, Culver City, CA 90232, United States

Issuing Office: The Office of Prescription Drug Promotion (OPDP), United States

RE: BLA 76133 . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products